Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study
Metrics: PDF 940 views | HTML 1306 views | ?
Takatsugu Ogata1, Hironaga Satake2, Misato Ogata1, Yukimasa Hatachi1, Kentaro Inoue3, Madoka Hamada3 and Hisateru Yasui1
1Department of Medical Oncology, Kobe City Medical Center General Hospital, Chuo-ku, Kobe City, Hyogo, 650-0047, Japan
2Cancer Treatment Center, Kansai Medical University Hospital, Shinmachi, Hirakata City, Osaka, 573-1191, Japan
3Department of Surgery, Kansai Medical University Hospital, Shinmachi, Hirakata City, Osaka, 573-1191, Japan
Hironaga Satake, email: firstname.lastname@example.org
Keywords: advanced gastric cancer; nivolumab; neutrophil-to-lymphocyte ratio; predictive factors; prognostic factors
Received: May 28, 2018 Accepted: September 08, 2018 Published: October 02, 2018
Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.
Methods: This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLRpre) and two weeks after the first administration (NLRpost).
Results: Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 – 265) and the median OS was 290 days (range, 21 – 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLRpre arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLRpost arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLRpre arm (290 vs. 175 days; p=0.008) and in the high NLRpost arm (290 vs. 69 days; p<0.001).
Conclusion: NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.